Canada Biopharmaceuticals Contract Manufacturing Market Size & Outlook
Global Market
Related Markets
Canada biopharmaceuticals contract manufacturing market highlights
- The Canada biopharmaceuticals contract manufacturing market generated a revenue of USD 2,992.7 million in 2025 and is expected to reach USD 7,122.5 million by 2033.
- The Canada market is expected to grow at a CAGR of 11.3% from 2026 to 2033.
- In terms of segment, mammalian was the largest revenue generating source in 2025.
- Non-mammalian is the most lucrative source segment registering the fastest growth during the forecast period.
Biopharmaceuticals contract manufacturing market data book summary
| Market revenue in 2025 | USD 2,992.7 million |
| Market revenue in 2033 | USD 7,122.5 million |
| Growth rate | 11.3% (CAGR from 2026 to 2033) |
| Largest segment | Mammalian |
| Fastest growing segment | Non-mammalian |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Mammalian, Non-mammalian |
| Key market players worldwide | Boehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, AGC Biologics, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Novartis AG ADR, Catalent Inc, ADMA Biologics Inc, Pfizer Inc, Siegfried Holding AG, Cambrex, Binex |
Other key industry trends
- In terms of revenue, Canada accounted for 6.7% of the global biopharmaceuticals contract manufacturing market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. biopharmaceuticals contract manufacturing market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 7,122.5 million by 2033.
Key factor which is expected the impact the biopharmaceutical development and marketing in Canada is the presence of regulatory bodies such as Biologics and Genetic Therapies Directorate (BGTD) of the Health Products and Food Branch (HPFB) of Health Canada in the country.
BGTD is engaged in the regulation of biological products including hemostatic agents, blood & blood products, hormones, bacterial & viral vaccines, gene & cell therapies cytokines, enzymes, allergenic extracts, monoclonal antibodies, developed in the country.
Growth in R&D being conducted in the country externally and through partnerships which receive funding and investment from small & medium-sized enterprises and other venture funds is expected to improve the demand for biopharmaceutical manufacturing in the country in the future.
No credit card required*
Publish Date: Aug 10, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biopharmaceuticals Contract Manufacturing Market Scope
Biopharmaceuticals Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| Samsung Electronics Co Ltd | View profile | 124,804 | 129, Samsung-ro, Yeongtong-gu, Gyeonggi-do, Suwon-si, Korea, Republic of, 443-742 | www.samsung.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Toyobo Co Ltd | View profile | 12,460 | 2-8, Dojima Hama 2-chome, Kita-ku, Osaka, Japan, 530-8230 | www.toyobo.co.jp |
| AGC Inc | View profile | 61,671 | 1-5-1, Marunouchi, Chiyoda-ku, Tokyo, Japan, 100-8405 | www.agc.com |
Canada Biopharmaceuticals Contract Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biopharmaceuticals Contract Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Mammalian was the largest segment with a revenue share of 63.45% in 2025.
Horizon Databook has segmented the Canada biopharmaceuticals contract manufacturing market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2021 to 2033.
Key factor which is expected the impact the biopharmaceutical development and marketing in Canada is the presence of regulatory bodies such as Biologics and Genetic Therapies Directorate (BGTD) of the Health Products and Food Branch (HPFB) of Health Canada in the country.
BGTD is engaged in the regulation of biological products including hemostatic agents, blood & blood products, hormones, bacterial & viral vaccines, gene & cell therapies cytokines, enzymes, allergenic extracts, monoclonal antibodies, developed in the country.
Growth in R&D being conducted in the country externally and through partnerships which receive funding and investment from small & medium-sized enterprises and other venture funds is expected to improve the demand for biopharmaceutical manufacturing in the country in the future.
- Canada Biopharmaceuticals Contract Manufacturing Market Source Outlook (Revenue, USD Million , 2021-2033)
- Mammalian
- Non-mammalian
- Canada Biopharmaceuticals Contract Manufacturing Market Service Outlook (Revenue, USD Million , 2021-2033)
- Process Development
- Fill & Finish Operations
- Analytical & QC Studies
- Packaging & Labelling
- Others
- Canada Biopharmaceuticals Contract Manufacturing Market Drug Type Outlook (Revenue, USD Million , 2021-2033)
- Biologics
- Biosimilars
- Canada Biopharmaceuticals Contract Manufacturing Market Type Outlook (Revenue, USD Million , 2021-2033)
- Drug Substance
- Finished Drug Product
- Canada Biopharmaceuticals Contract Manufacturing Market Scale of Operation Outlook (Revenue, USD Million , 2021-2033)
- Clinical
- Commercial
- Canada Biopharmaceuticals Contract Manufacturing Market Therapeutic Area Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Neurology
- Others
Reasons to subscribe to Biopharmaceuticals Contract Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biopharmaceuticals Contract Manufacturing Market Outlook databook
- Our clientele includes a mix of Biopharmaceuticals Contract Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Biopharmaceuticals Contract Manufacturing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Biopharmaceuticals Contract Manufacturing Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Canada Biopharmaceuticals Contract Manufacturing Market, 2021-2033 (US$M)
Canada Source - Biopharmaceuticals Contract Manufacturing Market Statistics, 2025 - 2033 (US$M)
